Circulating antithyroid antibodies contribute to the decrease of glomerular filtration rate in lithium-treated patients: a longitudinal study

Bocchetta, Alberto; Ambrosiani, Luca; Baggiani, Gioia; Pisanu, Claudia; Chillotti, Caterina; Ardau, Raffaella; Velluzzi, Fernanda; Piras, Doloretta; Loviselli, Andrea; Pani, Antonello

doi:10.1186/s40345-017-0114-4

Cited by 13 publications

(13 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Bocchetta et al. 31 first reported a link between renal function and the presence of thyroid antibodies including TPOAb and TGAb. They studied 394 patients who were treated with lithium.…”

Section: Discussionmentioning

confidence: 99%

Serum cystatin C is closely associated with euthyroid Hashimoto’s thyroiditis in adult female Chinese patients

Qin

Zhao

et al. 2020

J Int Med Res

View full text Add to dashboard Cite

Objective The aim of our study was to explore the association between serum cystatin C (CysC) and euthyroid Hashimoto’s thyroiditis. Methods There were 119 female euthyroid Hashimoto’s thyroiditis patients and 225 healthy controls who were recruited. Serum CysC, thyroid function, thyroid autoantibodies, fasting glucose, liver enzymes, and lipid profile were determined. Clinical parameters were compared between two groups. Results Serum CysC levels were significantly higher in euthyroid Hashimoto’s thyroiditis patients compared with controls. In the lowest, middle, and highest tertile groups of CysC, the percentage of Hashimoto’s thyroiditis was 15.9%, 34.2%, and 53.5%, respectively. The percentage of Hashimoto’s thyroiditis was significantly higher in the highest tertile than in the lowest and middle tertiles. Spearman’s correlation analysis showed that serum CysC levels were negatively correlated with free triiodothyronine (FT3), and positively correlated with serum thyroid peroxidase antibody (TPOAb) and thyroglobulin antibody (TGAb). Logistic regression analysis showed that serum CysC was independently related to the status of euthyroid Hashimoto’s thyroiditis. Conclusions The present study shows the first evidence suggesting that serum CysC levels are positively correlated with TPOAb and TGAb. Serum CysC might underlie the pathophysiologic features of euthyroid Hashimoto’s thyroiditis.

show abstract

“…Bocchetta et al. 31 first reported a link between renal function and the presence of thyroid antibodies including TPOAb and TGAb. They studied 394 patients who were treated with lithium.…”

Section: Discussionmentioning

confidence: 99%

Serum cystatin C is closely associated with euthyroid Hashimoto’s thyroiditis in adult female Chinese patients

Qin

Zhao

et al. 2020

J Int Med Res

View full text Add to dashboard Cite

show abstract

“…Gastro-intestinal complaints may be lessened by switching to another lithium preparation. Hypothyroidism is also possible and usually is treated with supplemental thyroid-hormone (Ambrosiani et al 2018; Bocchetta et al 2018). Hyperparathyroidism and consequent hypercalcemia can also arise during long-term treatment with lithium (Twigt et al 2013).…”

Section: Adverse Effects and Contraindicationsmentioning

confidence: 99%

Clinical use of lithium salts: guide for users and prescribers

Tondo

Alda

Bauer

et al. 2019

Int J Bipolar Disord

142

112

View full text Add to dashboard Cite

Background Lithium has been used clinically for 70 years, mainly to treat bipolar disorder. Competing treatments and exaggerated impressions about complexity and risks of lithium treatment have led to its declining use in some countries, encouraging this update about its safe clinical use. We conducted a nonsystematic review of recent research reports and developed consensus among international experts on the use of lithium to treat major mood disorders, aiming for a simple but authoritative guide for patients and prescribers. Main text We summarized recommendations concerning safe clinical use of lithium salts to treat major mood disorders, including indications, dosing, clinical monitoring, adverse effects and use in specific circumstances including during pregnancy and for the elderly. Conclusions Lithium continues as the standard and most extensively evaluated treatment for bipolar disorder, especially for long-term prophylaxis.

show abstract

“…In these patients, the rates per year of newly developed circulating thyroid antibodies and hypothyroidism were 1.7 and 1.5 %, respectively. Recently, Bochcetta et al [11] suggested also that, in lithium-treated patients, circulating antithyroid antibodies can contribute to the decrease of glomerular filtration rate.…”

Section: Introductionmentioning

confidence: 99%

No Connection between Long-Term Lithium Treatment and Antithyroid Antibodies

et al. 2019

View full text Add to dashboard Cite

Introduction The studies on the effect of lithium treatment on antithyroid antibodies showed either a higher concentration of these antibodies in patients receiving lithium compared to those lithium-naive or no difference between these groups. In lithium-treated bipolar patients, some researchers pointed to an association between antithyroid antibodies and other features of thyroid dysfunction such as hypothyroidism and decrease of glomerular filtration rate. Methods We compared antithyroid antibodies in 98 patients (30 male, 68 female) with bipolar disorder, aged 62±13 years, who received lithium for 19±10 years to 39 patients (12 male, 27 female), aged 57±10 years, who were never treated with lithium. The antibodies against thyroid peroxidase (TPOAb), against thyroglobulin (TGAb), and thyroid-stimulating hormone (TSH) receptors (TSHRAb) were estimated. Results No difference in the percentages of antibodies occurrence was found between groups, although the concentrations of TGAb were higher in patients receiving lithium. In lithium-treated patients, the presence of TPOAb was associated with lower concentrations of free triiodothyronine and the presence of TGAb, with higher concentrations of TSH. In females, the levels of TGAb were associated with lower thyroid volume. The concentrations of TPOAb correlated positively with the duration of lithium therapy in males, and those of TPOAb and TGAb negatively, with such duration, in female patients. Conclusion The results obtained showed no significant connection between long-term lithium treatment and antithyroid antibodies. In bipolar patients receiving lithium longitudinally, antithyroid antibodies can be associated with some indexes of thyroid function. However, they behave differently in male and female patients.

show abstract

Circulating antithyroid antibodies contribute to the decrease of glomerular filtration rate in lithium-treated patients: a longitudinal study

Cited by 13 publications

References 42 publications

Serum cystatin C is closely associated with euthyroid Hashimoto’s thyroiditis in adult female Chinese patients

Serum cystatin C is closely associated with euthyroid Hashimoto’s thyroiditis in adult female Chinese patients

Clinical use of lithium salts: guide for users and prescribers

No Connection between Long-Term Lithium Treatment and Antithyroid Antibodies

Contact Info

Product

Resources

About